HDAC2 and chronic myelogenous leukemia, BCR-ABL1 positive: exerted synergistic effects on imatinib resistance by inhibiting HDAC2 and the PI3K/Akt signal transduction pathway in chronic myelogenous leukemia (CML) cells with imatinib resistance [107].